MHC class I-associated peptides derive from selective regions of the human genome

Journal of Clinical Investigation

Volumn 126, Issue 12, 2016, Pages 4690-4701

  Pearson, Hillary ^a,b   Daouda, Tariq ^a,b   Granados, Diana Paola ^a,b   Durette, Chantal ^a   Bonneil, Eric ^a   Courcelles, Mathieu ^a   Rodenbrock, Anja ^a   Laverdure, Jean Philippe ^a   Côté, Caroline ^a   Mader, Sylvie ^a,b   Lemieux, Sébastien ^a,b,c   Thibault, Pierre ^a,c,d   Perreault, Claude ^a,b,c,e  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b Department of Medicine ^*  (United States)

^c Canadian National Transplant Research Program   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; HLA B ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ALLOTYPE; AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ARTICLE; AU RICH ELEMENT; B LYMPHOCYTE; CANCER CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; EXOME; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN GENOME; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SECONDARY STRUCTURE; RNA DEGRADATION; CD8+ T LYMPHOCYTE; FEMALE; GENETICS; IMMUNOLOGY; MALE;

B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENOME, HUMAN; HLA-A ANTIGENS; HLA-B ANTIGENS; HUMANS; MALE; PEPTIDES;

EID: 85002953687     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI88590     Document Type: Article

References (81)

1. Granados DP, Laumont CM, Thibault P, Perreault C. The nature of self for T cells-a systems-level perspective. Curr Opin Immunol. 2015;34:1-8.
2. Govern CC, Paczosa MK, Chakraborty AK, Huseby ES. Fast on-rates allow short dwell time ligands to activate T cells. Proc Natl Acad Sci USA. 2010;107(19):8724-8729.
3. Chakraborty AK, Weiss A. Insights into the initiation of TCR signaling. Nat Immunol. 2014;15(9):798-807.
4. Butler TC, Kardar M, Chakraborty AK. Quorum sensing allows T cells to discriminate between self and nonself. Proc Natl Acad Sci USA. 2013;110(29):11833-11838.
5. Caron E, et al. The MHC I immunopeptidome conveys to the cell surface an integrative view of cellular regulation. Mol Syst Biol. 2011;7:533.
6. Vrisekoop N, Monteiro JP, Mandl JN, Germain RN. Revisiting thymic positive selection and the mature T cell repertoire for antigen. Immunity. 2014;41(2):181-190.
7. Yewdell JW, Reits E, Neefjes J. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat Rev Immunol. 2003;3(12):952-961.
8. Hammer GE, Kanaseki T, Shastri N. The final touches make perfect the peptide-MHC class I repertoire. Immunity. 2007;26(4):397-406.
9. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunoge-netics. 1999;50(3-4):213-219.
10. Kim Y, Sidney J, Buus S, Sette A, Nielsen M, Peters B. Dataset size and composition impact the reliability of performance benchmarks for peptide-MHC binding predictions. BMC Bioinfor-matics. 2014;15:241.
11. de Verteuil D, Granados DP, Thibault P, Perreault C. Origin and plasticity of MHC I-associated self peptides. Autoimmun Rev. 2012;11(9):627-635.
12. Eisenlohr LC, Huang L, Golovina TN. Rethinking peptide supply to MHC class I molecules. Nat Rev Immunol. 2007;7(5):403-410.
13. Vigneron N, Van den Eynde BJ. Proteasome subtypes and the processing of tumor antigens: increasing antigenic diversity. Curr Opin Immunol. 2012;24(1):84-91.
14. Rock KL, Farfán-Arribas DJ, Colbert JD, Goldberg AL. Re-examining class-I presentation and the DRiP hypothesis. Trends Immunol. 2014;35(4):144-152.
15. Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annu Rev Immunol. 2013;31:443-473.
16. Goodenough E, et al. Cryptic MHC class I-binding peptides are revealed by aminoglycoside-induced stop codon read-through into the 3' UTR. Proc Natl Acad Sci USA. 2014;111(15):5670-5675.
17. Antón LC, Yewdell JW. Translating DRiPs: MHC class I immunosurveillance of pathogens and tumors. J Leukoc Biol. 2014;95(4):551-562.
18. Apcher S, Millot G, Daskalogianni C, Scherl A, Manoury B, Fåhraeus R. Translation of pre-spliced RNAs in the nuclear compartment generates peptides for the MHC class I pathway. Proc Natl Acad Sci USA. 2013;110(44):17951-17956.
19. Granados DP, et al. MHC I-associated pep-tides preferentially derive from transcripts bearing miRNA response elements. Blood. 2012;119(26):e181-e191.
20. Laumont CM, et al. Global proteogenomic analysis of human MHC class I-associated peptides derived from non-canonical reading frames. Nat Commun. 2016;7:10238.
21. Caron E, et al. An open-source computational and data resource to analyze digital maps of immunopeptidomes. Elife. 2015;4:e07661.
22. Hickman HD, et al. Toward a definition of self: proteomic evaluation of the class I peptide repertoire. J Immunol. 2004;172(5):2944-2952.
23. Mester G, Hoffmann V, Stevanovic S. Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands. Cell Mol Life Sci. 2011;68(9):1521-1532.
24. Hassan C, et al. The human leukocyte antigen-presented ligandome of B lymphocytes. Mol Cell Proteomics. 2013;12(7):1829-1843.
25. Hoof I, van Baarle D, Hildebrand WH, Kesmir C. Proteome sampling by the HLA class I antigen processing pathway. PLoS Comput Biol. 2012;8(5):e1002517.
26. Paul S, Weiskopf D, Angelo MA, Sidney J, Peters B, Sette A. HLA class I alleles are associated with peptide-binding repertoires of different size, affinity, and immunogenicity. J Immunol. 2013;191(12):5831-5839.
27. Granados DP, et al. Impact of genomic polymorphisms on the repertoire of human MHC class I-associated peptides. Nat Commun. 2014;5:3600.
28. Granados DP, et al. Proteogenomic-based discovery of minor histocompatibility antigens with suitable features for immunotherapy of hemato-logic cancers. Leukemia. 2016;30(6):1344-1354.
29. Daouda T, Perreault C, Lemieux S. pyGeno: A Python package for precision medicine and proteogenomics. F1000Research 2016;5(381). https://f1000research.com/articles/5-381/v2. Accessed October 31, 2016.
30. Elias JE, Gygi SP. Target-decoy search strategy for increased confidence in large-scale protein iden-tifications by mass spectrometry. Nat Methods. 2007;4(3):207-214.
31. Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, Nielsen M. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res. 2008;36(Web Server issue):W509-W512.
32. Karosiene E, Lundegaard C, Lund O, Nielsen M. NetMHCcons: a consensus method for the major histocompatibility complex class I predictions. Immunogenetics. 2012;64(3):177-186.
33. González-Galarza FF, et al. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acids Res. 2015;43(Database issue):D784-D788.
34. Sidney J, Peters B, Frahm N, Brander C, Sette A. HLA class I supertypes: a revised and updated classification. BMC Immunol. 2008;9:1.
35. Gallien S, Kim SY, Domon B. Large-Scale Targeted Proteomics Using Internal Standard Trig-gered-Parallel Reaction Monitoring (IS-PRM). Mol Cell Proteomics. 2015;14(6):1630-1644.
36. Bassani-Sternberg M, Pletscher-Frankild S, Jensen LJ, Mann M. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol Cell Proteomics. 2015;14(3):658-673.
37. Weinzierl AO, et al. Distorted relation between mRNA copy number and corresponding major his-tocompatibility complex ligand density on the cell surface. Mol Cell Proteomics. 2007;6(1):102-113.
38. Jovanovic M, et al. Immunogenetics. Dynamic profiling of the protein life cycle in response to pathogens. Science. 2015;347(6226):1259038.
39. Liu Y, Aebersold R. The interdependence of transcript and protein abundance: new data-new complexities. Mol Syst Biol. 2016;12(1):856.
40. Kim MS, et al. A draft map of the human pro-teome. Nature. 2014;509(7502):575-581.
41. Princiotta MF, et al. Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity. 2003;18(3):343-354.
42. Floor SN, Doudna JA. Tunable protein synthe-sis by transcript isoforms in human cells. Elife. 2016;5:e10921.
43. Calvo SE, Pagliarini DJ, Mootha VK. Upstream open reading frames cause widespread reduction of protein expression and are polymorphic among humans. Proc Natl Acad Sci USA. 2009;106(18):7507-7512.
44. Lorenz R, et al. ViennaRNA Package 2.0. Algorithms Mol Biol. 2011;6:26.
45. Szostak E, Gebauer F. Translational control by 3'-UTR-binding proteins. Brief Funct Genomics. 2013;12(1):58-65.
46. Schott J, Stoecklin G. Networks controlling mRNA decay in the immune system. Wiley Inter-discip Rev RNA. 2010;1(3):432-456.
47. Kudla G, Lipinski L, Caffin F, Helwak A, Zylicz M. High guanine and cytosine content increases mRNA levels in mammalian cells. PLoS Biol. 2006;4(6):e180.
48. Zhao W, Pollack JL, Blagev DP, Zaitlen N, McMa-nus MT, Erle DJ. Massively parallel functional annotation of 3' untranslated regions. Nat Bio-technol. 2014;32(4):387-391.
49. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545-15550.
50. Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015;4:e05005.
51. de Verteuil D, et al. Deletion of immunoprote-asome subunits imprints on the transcriptome and has a broad impact on peptides presented by major histocompatibility complex I molecules. Mol Cell Proteomics. 2010;9(9):2034-2047.
52. Liu Z, et al. GPS-ARM: computational analysis of the APC/C recognition motif by predicting D-boxes and KEN-boxes. PLoS One. 2012;7(3):e34370.
53. Rechsteiner M, Rogers SW. PEST sequences and regulation by proteolysis. Trends Biochem Sci. 1996;21(7):267-271.
54. Chen X, Qiu JD, Shi SP, Suo SB, Huang SY, Liang RP. Incorporating key position and amino acid residue features to identify general and species-specific Ubiquitin conjugation sites. Bioin-formatics. 2013;29(13):1614-1622.
55. Prakash S, Tian L, Ratliff KS, Lehotzky RE, Matouschek A. An unstructured initiation site is required for efficient proteasome-mediated degradation. Nat Struct Mol Biol. 2004;11(9):830-837.
56. van der Lee R, et al. Intrinsically disordered segments affect protein half-life in the cell and during evolution. Cell Rep. 2014;8(6):1832-1844.
57. Romero P, Obradovic Z, Li X, Garner EC, Brown CJ, Dunker AK. Sequence complexity of disordered protein. Proteins. 2001;42(1):38-48.
58. Jones DT, Cozzetto D. DISOPRED3: precise disordered region predictions with annotated protein-binding activity. Bioinformatics. 2015;31(6):857-863.
59. Dosztányi Z, Csizmok V, Tompa P, Simon I. IUPred: web server for the prediction of intrin-sically unstructured regions of proteins based on estimated energy content. Bioinformatics. 2005;21(16):3433-3434.
60. Alexa A, Rahnenfuhrer J. topGO: Enrichment Analysis for Gene Ontology. R package version 2.24.0. https://bioconductor.org/packages/release/bioc/html/topGO.html. Accessed October 5, 2016.
61. Caron E, Kowalewski DJ, Chiek Koh C, Sturm T, Schuster H, Aebersold R. Analysis of Major Histocompatibility Complex (MHC) Immuno-peptidomes Using Mass Spectrometry. Mol Cell Proteomics. 2015;14(12):3105-3117.
62. Concha M, et al. Identification of new viral genes and transcript isoforms during Epstein-Barr virus reactivation using RNA-Seq. J Virol. 2012;86(3):1458-1467.
63. Klijn C, et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat Biotech-nol. 2015;33(3):306-312.
64. Benoist C, Germain RN, Mathis D. A plaidoy-er for 'systems immunology'. Immunol Rev. 2006;210:229-234.
65. Longhi S. Structural disorder in viral proteins. Protein Pept Lett. 2010;17(8):930-931.
66. Murat P, Tellam J. Effects of messenger RNA structure and other translational control mechanisms on major histocompatibility complex-I mediated antigen presentation. Wiley Interdiscip Rev RNA. 2015;6(2):157-171.
67. Sansom SN, et al. Population and single-cell genomics reveal the Aire dependency, relief from Polycomb silencing, and distribution of self-antigen expression in thymic epithelia. Genome Res. 2014;24(12):1918-1931.
68. St-Pierre C, Trofimov A, Brochu S, Lemieux S, Perreault C. Differential Features of AIRE-Induced and AIRE-Independent Promiscuous Gene Expression in Thymic Epithelial Cells. J Immunol. 2015;195(2):498-506.
69. Brennecke P, et al. Single-cell transcriptome analysis reveals coordinated ectopic gene-expression patterns in medullary thymic epithelial cells. Nat Immunol. 2015;16(9):933-941.
70. Schumacher TN, Schreiber RD. Neoanti-gens in cancer immunotherapy. Science. 2015;348(6230):69-74.
71. Robbins PF, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19(6):747-752.
72. Yadav M, et al. Predicting immunogenic tumour mutations by combining mass spec-trometry and exome sequencing. Nature. 2014;515(7528):572-576.
73. Blankenstein T, Leisegang M, Uckert W, Sch-reiber H. Targeting cancer-specific mutations by T cell receptor gene therapy. Curr Opin Immunol. 2015;33:112-119.
74. Zerbino DR, Wilder SP, Johnson N, Juettemann T, Flicek PR. The ensembl regulatory build. Genome Biol. 2015;16:56.
75. Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol. 2016;34(5):525-527.
76. Wilkins MR, et al. Protein identification and analysis tools in the ExPASy server. Methods Mol Biol. 1999;112:531-552.
77. Rice P, Longden I, Bleasby A. EMBOSS: the European Molecular Biology Open Software Suite. Trends Genet. 2000;16(6):276-277.
78. Dosztányi Z, Mészáros B, Simon I. Bioinfor-matical approaches to characterize intrinsically disordered/unstructured proteins. Brief Bioinfor-matics. 2010;11(2):225-243.
79. Kuhn M, et al. caret: Classification and Regression Training. https://github.com/topepo/caret/. Published August 5, 2016. Accessed October 5, 2016.
80. Venables WN, Ripley BD. Modern applied statistics with S. Fourth edition. New York: Springer-Verlag; 2002.
81. Lawrence RT, et al. The proteomic landscape of triple-negative breast cancer. Cell Rep. 2015;11(4):630-644.